Early vs Delayed Intravesical Blad-Care During BCG Therapy
Recruiting
N/A
Interventional Study
Urinary Bladder Neoplasms
BCG-Induced Cystitis
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 19 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Supportive Care
- Participants needed
- 56 (estimated)
- Sponsor
- BLAD-HYA Group · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
Intravesical Bacillus Calmette-Guérin (BCG) therapy is the standard adjuvant treatment for patients with intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC). However, BCG therapy frequently induces local bladder irritation symptoms including urinary frequency, urgency, dysuria, hematuria, and suprapubic pain, which may reduce quality of life and lead to treatment interruption.
…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Adults aged ≥19 years
* Histologically confirmed non-muscle-invasive bladder cancer
* Candidates for intravesical BCG therapy
* Negative urine culture prior to BCG therapy
* Ability to provide written informed consent
Exclusion Criteria:
* Hypersensitivity to components of B…
Contacts